Navigation Links
China Medical Technologies Announces Receipt of Korean FDA Approval for its HIFU System
Date:10/15/2007

BEIJING, Oct. 15 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic products and high intensity focused ultrasound ("HIFU") tumor therapy systems, today announced that it has received official approval from the Korean Food and Drug Administration (the "KFDA") to market its HIFU tumor therapy system in Korea for the treatment of liver cancer, pancreatic cancer and uterine fibroids.

"KFDA approval is another significant milestone in attaining international recognition for our HIFU system, particularly after having received conditional approval from the U.S. Food and Drug Administration in July 2007 to commence human clinical trials," stated Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We are pleased to introduce our HIFU system to Korean patients and excited about the opportunity to commence our HIFU sales outside of China."

Cancer is the leading cause of death in Korea and the number of Korean cancer patients is increasing. The introduction of the Company's HIFU tumor therapy system to Korean hospitals will provide patients with a tumor treatment alternative that can also compliment conventional treatment approaches.

There are over 1,000 general hospitals in Korea. The Company's exclusive distributor in Korea will initially target the large general hospitals in Korea to promote our HIFU tumor therapy system. The Company and its distributor will periodically review the Company's sales strategy for the Korean market with a particular focus on the Company's long-term market position in Korea.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostics products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the Company's expectations with respect to sales in Korea and international recognition of its HIFU tumor therapy system contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For more information, please contact:

Winnie Fan

China Medical Technologies, Inc.

Tel: +86-10-6530-8833

Email: IR@chinameditech.com


'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. China tells officials not to hide SARS damage
2. China reports declining number of SARS Cases
3. China says patient may have SARS
4. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
5. Adverse Effects Associated with Unauthorised Hepatitis A Vaccine in China
6. Pig Bacterium (Streptococcus suis) Kills 24 In China
7. Watch Out! Pollution hazard from E-waste recycling in India & China
8. French Fries In Cancer Controversy In China
9. China To Distribute Free Condoms To Combat AIDS/HIV
10. HIV Cases Steadily Increasing In China With The Toll Over 1.26 Lakh
11. India And China Discuss Import Of Encephalitis Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort ... has recently developed and published an informational resource that addresses frequently asked questions. ... common inquiries the site’s team of third party administrator (TPA) contributors regularly receives ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... 2017 , ... Oily skin is a common and unwelcomed occurrence in people of all ages, ... to offer to the discussion of dealing with excess skin oil. “Oily skin is a ... remedies that can help remove the oily shine while keeping the skin fresh and clean,” ...
(Date:3/27/2017)... Aurora, CO (PRWEB) , ... March 27, 2017 , ... ... Dr. Mark Braasch for leading sleep apnea treatment, with or without a referral. Sleep ... the condition, which can include daytime sleepiness, morning headaches and chronic snoring. , ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... BOSTON , March 28, 2017 /PRNewswire/ ... today announced a partnership with premium news ... allows pharmaceutical companies to extract key insights from ... text mining technology. The Linguamatics I2E ... top 20 global pharmaceutical companies. The Linguamatics-Dow Jones ...
(Date:3/28/2017)... Md. , March 28, 2017  CASI ... to innovative therapeutics addressing cancer and other unmet ... the American Association for Cancer Research annual meeting.  ... 3 is entitled "Evaluation of ENMD-2076 in ... and the second poster to be presented on ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
Breaking Medicine Technology: